Skip to Main Content
Newsroom
Get in Touch
LinkedIn
Editas Medicine Linkedin
Research and Pipeline
CRISPR Gene Editing
For Patients
Who We Are
Join Our Team
Investors
Newsroom
Get in Touch
LinkedIn
Purchasing Policy Terms and Conditions
+
-
Editas Newsroom
Nov
17
Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial
Nov
2
Editas Medicine Announces Third Quarter 2022 Results and Business Updates
Oct
26
Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update